Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP)-Reference-Cited by-同舟云学术

Regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP)

Published:2022-06-03 Issue:9 Volume:50 Page:1203-1209
ISSN:0300-5577
Container-title:Journal of Perinatal Medicine
language:en
Short-container-title:

Author:

Hart Jessica M.¹^ORCID,Hakim Joe B.²,Wylie Blair J.¹,Beam Andrew L.³⁴

Affiliation:

1. Department of Maternal-Fetal Medicine , Beth Israel Deaconess Hospital , Boston , MA , USA

2. Harvard-MIT Department of Health Sciences and Technology , Cambridge , MA , USA

3. Department of Epidemiology, Harvard T.H. Chan School of Public Health , Boston , MA , USA

4. Department of Biomedical Informatics, Harvard Medical School , Boston , MA , USA

Abstract

Abstract Objectives To describe regional differences in utilization of 17α-hydroxyprogesterone caproate (17-OHP). Methods Retrospective cohort study of a large, US commercial managed care plan claims database with pharmacy coverage from 2008 to 2018. Singleton pregnancies with at least one prior spontaneous preterm birth (sPTB) were included. Regional and state-based differences in 17-OHP use were compared. Data were analyzed using t-tests and Fisher’s exact tests. Results Of the 4,514 individuals with an indication for 17-OHP, 580 (12.8%) were prescribed 17-OHP. Regional and state-based differences in 17-OHP utilization were identified; Northeast 15.7%, Midwest 13.7%, South 12.0%, and West 10.4% (p=0.003). Conclusions While significant regional differences in 17-OHP utilization were demonstrated, 17-OHP utilization remained low despite this cohort having insurance through a US commercial managed care plan. Suboptimal utilization demonstrates a disconnect between research and uptake in clinical practice. This underscores a need for implementation science in obstetrics to translate updated recommendations more effectively and efficiently into clinical practice.

Funder

National Heart, Lung, and Blood Institute

Publisher

Walter de Gruyter GmbH

Subject

Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health

Link

https://www.degruyter.com/document/doi/10.1515/jpm-2021-0586/pdf

Reference24 articles.

1. Society for Maternal-Fetal Medicine (SMFM) Publications Committee. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth. Am J Obstet Gynecol 2017;216:B11–3. https://doi.org/10.1016/j.ajog.2017.01.022.

2. Practice bulletin no. 130. Prediction and prevention of preterm birth. Obstet Gynecol. 2012;102:964–73. https://doi.org/10.1097/00006250-200310000-00043.

3. Meis, PJ, Klebanoff, M, Thom, E, Dombrowski, MP, Sibai, B, Moawad, AH, et al.. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85. https://doi.org/10.1056/NEJMoa035140.

4. Blackwell, SC, Gyamfi-Bannerman, C, Biggio, JR, Chauhan, SP, Hughes, BL, Louis, JM, et al.. 17-OHPC to prevent recurrent preterm birth in singleton gestations (PROLONG study): a multicenter, international, randomized double-blind trial. Am J Perinatol 2020;37:127–36. https://doi.org/10.1055/s-0039-3400227.

5. Stewart, LA, Simmonds, M, Duley, L, Llewellyn, A, Sharif, S, Walker, RAE, et al.. Evaluating progestogens for preventing preterm birth international collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. Lancet 2021;397:1183–94. https://doi.org/10.1016/S0140-6736(21)00217-8.